Navigation Links
Corgenix Reports Financial Results for First Quarter of Fiscal 2009
Date:11/13/2008

DENVER, Nov. 13 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, reported sales of $2,001,896 for the first fiscal quarter ended September 30, 2008, compared with $2,105,188 for the quarter ended September 30, 2007, a decrease of 4.9%. Excluding revenues from contract manufacturing, Corgenix sales increased 9.6% over the same period in the prior fiscal year.

The first quarter of fiscal 2009 produced an operating loss of $94,133 compared with operating income of $2,023 for the first quarter of fiscal 2008. The net loss for the quarter was $340,659 or $0.01 per share, compared to a net loss of $688,129, or $0.04 per share, in the year earlier quarter. The primary causes of the reduced net loss for the current quarter were the reductions in the cost of sales as a percentage of sales from 45.8% in the previous year to 44.6% in the current quarter, in addition to the reduced interest expense, from $680,324 in the prior year to $252,611 in the current quarter.

During the first quarter of fiscal 2009, Corgenix was again named one of Colorado's 50 fastest growing technology companies in Colorado in a list compiled by Deloitte & Touche.

"During the quarter, we saw solid growth in sales of most Corgenix products and were successful in cutting our quarterly net loss in half," said Douglass Simpson, Corgenix President and CEO. "The decrease in total revenue was mainly due to the loss of some contract manufacturing business, but we remain optimistic that we will replace that part of our business later this year with some exciting new strategic alliances."

Mr. Simpson added, "We believe the remainder of this fiscal year will begin to reflect a number of additional accomplishments including the efforts we continue to put forth in growing our AspirinWorks business."

First Quarter Fiscal 2009 Conference Call Details

Corgenix invites all those interested in hearing management's discussion of fiscal year results to join a shareholders conference call on Thursday, November 13, 2008, at 4:00 PM EST (2:00 PM MST). Interested parties can join the call by dialing (800) 895-0198. International participants may access the call by dialing +1 785 424 1053. The conference code is "CORGENIX." A replay will be available for 30 days following the call by dialing (800) 723-0544 for U.S. participants and +1 402 220 2656 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at http://www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.

SUMMARY OF FINANCIAL HIGHLIGHTS

($000 of U.S. dollars except shares outstanding and per share amounts)

CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES

OPERATIONAL DATA

Quarter Ended September 30

2008 2007

Net sales $2,002 $2,105

Gross profit 1,107 1,149

Operating income (loss) (94) 2

Net loss (341) (688)

Basic and diluted loss

per share $(0.01) $(0.04)

Basic and Diluted shares

outstanding 30,092,093 19,340,384

BALANCE SHEET DATA

September 30, 2008 June 30, 2008

Cash $1,023 $1,520

Working capital 2,513 2,889

Total assets 7,337 7,888

Long-term debt 1,129 1,276

Total stockholders' equity 3,886 4,153


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Corgenix Announces Expansion of Hemorrhagic Fever Virus Product Development Program
2. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
3. Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver
4. MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Spheris Reports Third Quarter 2008 Results
6. MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results
7. Symmetry Medical Reports Third Quarter 2008 Financial Results
8. EntreMed Reports Clinical Program Progress and Company Update
9. NBTY Reports Fourth Quarter and Fiscal Year Results
10. IPC The Hospitalist Company Reports Record Third Quarter 2008 Results
11. Consumer Reports Survey: Nearly Half of Adults Wont Get Flu Vaccine, Citing Poor Excuses Like I Dont Get Sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra ... care advancements to physician colleagues, skilled nursing facility medical directors and other clinicians ... Waters of Wound Care." , "At many of these conferences we get to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... management, presents its enhanced Pepper Flow promotional review platform at the Promotional ... Flow’s increased insight-driven capabilities help marketers streamline the medical, legal, and regulatory ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: